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Biomarkers are biological measures of a biological state. An ideal marker should be safe
and easy to measure, cost efficient, modifiable with treatment, and consistent across
gender and ethnic groups. To date, none of the available biomarkers satisfy all of these
criteria. In addition, the major limitations of these markers are low specificity, sensitivity,
and false positive results. Recently identified, microRNAs (miRNAs) are endogenous,
evolutionarily conserved small non-coding RNA (about 22–25 nt long), also known as
micro-coordinators of gene expression, which have been shown to be an effective tools
to study the biology of diseases and to have great potential as novel diagnostic and prog-
nostic biomarkers with high specificity and sensitivity. In fact, it has been demonstrated
that miRNAs play a pivotal role in the regulation of a wide range of developmental and
physiological processes and their deficiencies have been related to a number of disease.
In addition, miRNAs are stable and can be easily isolated and measured from tissues and
body fluids. In this review, we provide a perspective on emerging concepts and potential
usefulness of miRNAs as diagnostic markers, emphasizing the involvement of specific
miRNAs in particular tumor types, subtypes, cardiovascular diseases, diabetes, infectious
diseases, and forensic test.
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Introduction
The ideal biomarker should be non-invasive, specific, cost efficient, quantifiable, robust, translatable,
predictive, and sensitive. Physicians, Scientists, and epidemiologists use biomarkers for monitoring,
screening, diagnostics, and prognostics of various diseases (1). It is established that disease-related
biomarkers including proteins (antigens, enzymes), lipid, and electrolyte components, could be
segregated from cells or tissues with current disease and exist in the blood (2). Current available
serum/plasma biomarkers are mostly based on proteins. The major limitations of these markers are
low specificity, sensitivity, and false positive results. One example amongmany is given by the serum
prostate-specific antigen (PSA), which has been used for screening men with an existing diagnosis
of prostate cancer (PCa) and is used as a marker for identifying recurring disease subsequent to
treatment. However, PSA-based screening is also associated with over diagnosis and overtreatment.
The fact that PSA is synthesized by all prostate epithelial cells, whether normal, hyperplastic, or
cancerous, weakens the specificity of PSA as a cancer biomarker. Elevated serum PSA levels may
reflect the presence of cancer or may be caused by benign prostatic hyperplasia (BPH), infection,
and chronic inflammation (3).
microRNAs (miRNAs) are endogenous, evolutionarily conserved, naturally abundant, relatively
stable, small (about 22 nt long) non-coding RNA molecules that function as post-transcriptional
gene regulation in most biological and pathological process (4, 5).
It has been estimated that over 30% of protein-coding genes are regulated by miRNAs either
by complementary binding of target mRNA or binding to imperfect complementary sites in the
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30 untranslated regions (30UTR), leading to control of expression
of these genes at the level of translation (4, 6, 7). It has been
also calculated that above 45,000 miRNAs target sites are present
in the human 30UTR and above 60% of human protein-coding
genes are probably regulated bymultiplemiRNAs (8).miRNAs are
transcribed in the nucleus as a long, capped, poly-adenylated pre-
cursor called primarymiRNA (pri-miRNA) by a RNApolymerase
II or III (9, 10). This pri-miRNA is processed by the ribonuclease
(RNase) III called Drosha or the double-stranded DNA-binding
Protein called DGCR8/Pasha(11) producing a precursor miRNA
(pre-miRNA). The nuclear export receptor exportin 5/Ran GTP
actively transports pre-miRNAs to the cytoplasm (12, 13). Then,
Pre-miRNAs are processed by the RNase III endonuclease Dicer
along with the trans-activation-responsive RNA-binding protein
(TRBP) and produced a small double-stranded RNA structure
(22 nt). This duplex miRNA is unwound into mature single-
stranded form and integrate into the RNA-induced silencing com-
plex (RISC), which escorts the complex into the complementary
30UTR of the target mRNA.
In 2008, circulating miRNAs were identified in blood plasma,
platelets, leukocytes, and erythrocytes. Even in the adverse condi-
tions (high or low PH, boiling, freeze–thaw cycle, and long-term
storage at room temperature), plasma miRNAs were found to be
stable (14, 15). Recently, several studies suggested that plasma
miRNAs may be packaged into the exosomes, microvesicles, and
apoptotic bodies or associated with the RNA-binding proteins
(Arogonaute2) or lipoprotein complex (HDL) to protect their
degradation fromRNase. CirculatingmiRNAmaymediate distant
cell–cell communication, probably to regulate gene expression
(16, 17).
Most interestingly, circulating miRNAs have many necessary
features of ideal biomarkers. Stable miRNAs have been found
in various biological fluids, such as plasma, serum, saliva, milk,
cerebrospinal fluids, and markedly expression motifs of serum
miRNAs, are firmly linked to various diseases including can-
cer. The quantity of miRNAs can be easily estimated by various
methods, such as Microarray, Hybridization, Deep-sequencing,
qRT-PCR, and microbeads analysis.
microRNAs have been demonstrated to play a major role in
a wide range of developmental processes including metabolism,
apoptosis, cell proliferation, stem cell division, muscle differenti-
ation, and brain morphogenesis (18–20). Since this pivotal role in
the regulation of these processes related to development and other
physiological functions, miRNAs deficiencies have been linked to
a number of diseases ranging from cancer to autoimmune disease.
The aim of this review is to emphasize the great potential of
circulating miRNAs as very specific and sensitive biomarkers for
diagnosis of tumor and other diseases.
miRNAs in Diagnosis of Cancer
During the present time, circulating miRNAs are going to the
new era of cancer diagnosis and prognosis. Anomalous levels of
extracellular miRNAs have been assessed in several cancers, such
as hematological and solid neoplasms (summarized in Table 1).
In 2008, Lawrie et al. showed that levels of serum miRNA-
21were associated with diagnosis and prognosis in diffuse large
B-cell lymphoma (DLBCL) patients (21). More recently, Chen
et al. confirmed these results in the sera of Chinese DLBCL
patients compared to healthy controls (47). Acute myeloid
leukemia (AML) is another type of common hematological can-
cer in adults. Fayyad-Kazan et al. showed that the expression of
two important plasma miRNAs (miR-150 andmiR-342) was up-
regulated compared to healthy controls, suggesting that these two
miRNAs could be novel, potential, and specific biomarkers for
early diagnosis of AML (22). Besides DLBCL and AML, extra-
cellular miRNAs have been also reported in chronic lymphocytic
leukemia (CLL). A recent study demonstrated that circulating
miR-195, miR-29a, and miR-222 levels are the better indicators
to separate B-cell CLL patients from healthy controls (48). In
addition, high level of plasma miR-155 seems to be an early
detector of the disease (23).
The most common type of lung cancer, non-small cell lung
cancer (NSCLC), can be diagnosed in various stages using cell-free
non-invasive miRNAs.
Recently, two validated serum miRNAs (miR-25 and miR-223)
have been reported to be involved in the tumorigenic process
and significantly increased in NSCLC patients, suggesting their
potential use in early diagnosis of this lethal neoplasm (15).
Different studies focused on the identification of plasma and
serum miRNAs signatures, which could exploit as early stage
diagnostic markers for NSCLC. For example, serum-based two
miRNAs panel (miR-1254, miR-574-5p) is significantly increased
in early stage NSCLC (24), and a plasma based three miRNAs
panel (miR-155, miR-197, miR-182) is notably increased in stage-
I NSCLC (25). A plasma based four miRNAs panel (miR-21,
miR-126, miR-210, miR-182) is differentially expressed in stage-I
NSCLC; and furthermore, this panel can be used for differentiate
lung adenocarcinoma from squamous cell cancer (49). Lastly, a
serum-based 10 miRNAs panel (miR-20a, miR-24, miR-25, miR-
145, miR-152, miR-199a-5p, miR-211, miR-222, miR-223, miR-
320) is significantly and differentially expressed in early NSCLC
patients (50).
Cancer of the PCa is now recognized as one of the most impor-
tant medical problems facing the male population. Historically,
serum PSA has been used for screening men with an existing
diagnosis of PCa and has been regarded as an ideal marker for
identifying recurring disease subsequent to treatment (51). How-
ever, PSA-based screening is associated with over diagnosis and
overtreatment (52).
Although Mitchell et al. first reported that serum miR-141 is
very sensitive biomarkers to detect PCa, different and contra-
dictory results were obtained by Mahn and co-authors (14, 53).
Other studies showed that extracellular miR-375 and miR-141
were most optimistic markers in the diagnosis of this neoplasm
(26). Urine, another important source of circulating miRNA,
has been widely exploited for the diagnosis of urological cancer.
Bryant et al. showed that miRs 107 and 574-3p were signifi-
cantly higher in the urine of PCa patients compared to healthy
groups, and would perform even better than PCA3 normalized to
PSA in identifying the presence of PCa (27). Other recent stud-
ies reported that urine miR-205 and miR-214 were significantly
down-regulated in PCa patients with 80% specificity and 89%
sensitivity (28).
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TABLE 1 | Circulating microRNAs a potential biomarkers in human cancers.
Cancer type miRNA Source Expression Significance Reference
Hematological cancer miR-21 Serum Up Diagnosis of DLBCL disease (21)
miR-150, miR-342 Plasma Up AML vs. healthy controls (22)
miR-155 Plasma Up CLL vs. healthy controls (23)
Lung cancer miR-25, miR-223 Serum Up Diagnosis of NSCLC disease (15)
miR-1254, miR-574-5p Serum Up Diagnosis of early stage NSCLC patients vs.
controls
(24)
miR-155, miR-197, miR-182 Plasma Up Diagnosis of in stage-I NSCLC disease (25)
Prostate miR-375, miR-141 Plasma Down PCa patient vs. BPH controls (26)
MiR-107, miR-574-3P Urine Up PCa vs. healthy controls (27)
miR-205, miR-214 Urine Down PCa vs. healthy controls (28)
Pancreatic Index I (4 miRNAs) and Iindex II
(10 miRNAs)
Whole blood Differential Early detection of pancreatic cancer vs.
healthy controls
(29)
Hepatocellular carcinoma miR-16, miR-199a Serum Down HCC vs. chronic liver disease. miR-16 with
AFP and AFP-L3 tumor protein markers
increased sensitivity and specificity of HCC
diagnosis
(30)
MiR-15b, miR-130b, and miR-16 Serum Up HCC discriminate HBV hepatitis patients, and
also sensitive rather than other tumor
biomarkers for diagnosis of HCC
(31, 32)
miR-625, miR-618, miR-532, miR-650,
miR-516-5p
Urine Differential HCC (HCV positive) group vs. healthy controls (33)
Colorectal cancer miR-29a, miR-92, miR-601, miR-760 Plasma Differential Early diagnosis of CRC vs. healthy controls (34, 35)
miR-31, miR-181b, miR-92, miR-203
and miR-21, let-7g
Serum Differential Good biomarkers for diagnostic of CRC
compared with single protein biomarkers
(36)
miR-200c Serum Up Diagnosis of CRC lymph node metastasis (37)
Gastric cancer miR-18a Plasma Up GC vs. healthy controls (38)
miR-122, miR-192 Plasma Differential Diagnosis of distant metastasis in GC disease (39)
Ovarian cancer miR-205, miR-let-7f Plasma Differential Epithelial ovarian cancers (EOC) vs. healthy
controls
(40)
Esophageal miR-21 Serum Up Esophageal cancer and BTC vs. controls (41, 42)
Cervical miR-218 Serum Down Diagnosis of cervical adenocarcinoma and
lymphatic metastasis
(43)
Thyroid let-7f, miR-151-5p, miR-222 Serum Up Diagnosis of papillary thyroid cancer (PTC) (44)
Astrocytomas miR-15b*, miR-23a, miR-133a,
miR-150*, miR-197, miR-497,
miR-548b-5p
Serum Down Diagnosis of malignant astrocytomas with
specificity and sensitivity
(45)
Head and neck miR-125a, miR-200a Saliva Down Oral squamous cell carcinoma patients vs.
control subjects
(46)
Bladder miR-125b and mir-126 Urine Differential Diagnosis of bladder cancer (46)
PCa, prostate cancer; BPH, benign prostatic hyperplasia, HCC, hepatocellular carcinoma; CRC, colorectal cancer; GC, gastric cancer; BTC, biliary tract cancer.
Pancreatic cancer is the fourth most common cause of can-
cer death in the Western world. The prognosis is poor, with 1-
and 5-year survival rates of only 20 and 6%. Early diagnosis of
pancreatic cancer is difficult, and no biomarkers in blood can
identify patients with pancreatic cancer at an early stage. In a
recent and promising study, Schultz and colleagues identified two
diagnostic panels based on miRNA expression in whole blood
with the potential to distinguish patients with pancreatic cancer
from healthy controls (29).
Hepatocellular carcinoma (HCC), a form of primary liver can-
cer, tends to develop in a setting of chronic infection with HBV
or HCV viruses, genetic defects, liver injury, or alcohol misuses.
Several studies have tried to use extracellular miRNAs for distin-
guish HCC from other liver disease. Qu et al. reported that serum
miR-16 andmiR-199a are significant and specifically decreased in
HCC compared to chronic liver disease patients. In addition they
demonstrated that combiningmiR-16withAFP and Lens culinaris
agglutinin-reactive AFP (AFP-L3) tumor markers could increase
sensitivity and specificityin the diagnosisofHCC (30). MiR-15b,
miR-130b, and miR-16 are potential, specific diagnostic markers
in discriminate between HCC andHBV hepatitis patients, and for
early detection of liver cancer as compared to others serum cancer
biomarkers such as AFP, des-γ-carboxyprothrombin (DCP), and
AFP-L3 (31, 32).
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Recently, Abdalla et al. showed that in urine sample, the levels
of threemiRNAs (miR-625,miR-618,miR-532) are high and levels
of two miRNAs (miR-650, miR-516-5p) are very low as compared
to the HCC (HCV positive) group and the control groups (33).
Colorectal cancer (CRC) is the thirdmost commonly diagnosed
cancer and the third cardinal cause of cancer death in the world.
Early diagnosismay risk-free of CRC and can easier target therapy.
In several ongoing studies,miRNAs showed to be promising sensi-
tive and specific early detectingmolecular biomarkers. Up to date,
plasma levels of miR-29a and miR-92 are significantly increased
whereas levels ofmiR-601 andmiR-760 are significantly decreased
in the early stage of CRC as compared to healthy individuals (34,
35). Recently,Wang et al. reported that inCRC, four cell-free miR-
NAs (miR-31, miR-181b, miR-92, miR-203) are down-regulated
and two miRNAs (miR-21, let-7g) are up-regulated, being more
sensitive and specific in the identification of CRC than any single
protein biomarker like CEA or CA19-9 (36). Moreover, has been
reported that a combination of seven exosomal miRNAs (let-7a,
miR-23a, miR-21, miR-150, miR-223, and miR-1229) might be
used for early detection of CRC, being significantly increased as
compared to healthy groups. In addition, high levels of serum
miR-200c in CRC patients have been reported to have a powerful
interrelationship with lymph node metastasis (37).
Gastric cancer (GC) is another leading cause of cancer death
in the world. For GC diagnosis, fewer numbers of sensitive
and specific markers are available. Several studies showed that
many extracellular miRNAs are promising and sensitive specific
biomarker for early diagnosis of GC (54). More recently, Tsu-
jiura et al. reported that plasma levelsof miR-18a are significantly
increased in GC patients (38). In addition, a five miRNAs panel
(miR-16, miR-25, miR-92a, miR-451, and miR-486-5p) was iden-
tified in plasma as a potential biomarker for early diagnosis of
GC (55). Moreover, another study showed that the plasma miR-
122 was down-regulated and plasma miR-192 was up-regulated
in GC patients andmight be used for the early diagnosis of distant
metastasis (39).
Briefly, circulating miRNAs have been proven to be useful
diagnostic/prognostic markers in other tumors. A two miRNAs
signature (high levels of miR-205 and low levels of miR-let-7f)
in the plasma of epithelial ovarian cancer (EOC) patients could
be able to identify with high specificity and sensitivity EOC
patients eventually stage-I disease (40), improving their chances
of therapeutic intervention.
Many individual circulating miRNA showed significant asso-
ciation with early cancer diagnosis’s, such as miR-21 levels, that
increase in esophageal cancer patients and interestingly together
with ROS analysis could be diagnostic for biliary tract cancer
(BTC), miR-210 levels are increased in conventional renal cell car-
cinoma (cRCC) patients, miR-218 levels are significantly reduced
in advance stage cervical cancer, cervical adenocarcinoma, and
lymphatic metastasis (41–43, 56, 57). In addition, a three miR-
NAs panel (let-7f, miR-151-5p and miR-222) are significantly
up-regulated in sera of papillary thyroid cancer (PTC) patients
(44). Moreover, a seven miRNAs panel (miR-15b*, miR-23a, miR-
133a, miR-150*, miR-197, miR-497, and miR-548b-5p) is notably
reduced in astrocytomas patients, with high sensitivity (88.00%)
and specificity (97%) (45).
Furthermore, saliva two miRNAs (miR-125a, miR-200a) were
found in reduced in oral squamous cell carcinoma patients.
In addition, two validated urine miRNAs (miR-125b and mir-
126) are indicated as, highly sensitive (80%), specific (100%),
and non-invasive biomarker for bladder cancer diagnosis and
prognosis (46).
miRNA Signatures Can Differentiate
Between Tumor Subtype
Formalin-fixed paraffin-embedded (FFPE) tissues are a very valu-
able source for biomarker discovery and validation. Quantity,
quality, and the integrity of mRNA into FFPE tissues are not opti-
mal due degradation or cross-linking with proteins and various
chemical (58, 59). miRNAs are small size and potentially more
stable to degradation than mRNAs during the formalin fixing
procedures. Recently, many studies supported and proved that
miRNAs are minimally affected by FFPE and, for example, can be
simply detected by qRT-PCR in archived liver andCRC specimens
up to 30 and 10 years, respectively (60–62).
Identification of tumor subtype is instrumental for patient
treatment and therefore survival and the peculiar patterns of
miRNAs expression in the individual type of tumor can boost this
classification (Table 2).
Breast cancer is a highly heterogeneous disease with different
molecular alteration, which result in its classification into five
intrinsic subtypes (luminal A and B, HER2-enriched, basal-like
and normal-like) (75, 76). The original molecular classification
is based on investigations on frozen tissue, and it is not appli-
cable to FFPE material, jeopardizing the wide application in the
clinical practice. Recently, several studies reported that deregula-
tion of miRNAs expression was strongly associated to molecular
breast cancer subtype. In fact, in plasma, the combination of
our (miR-29a, miR-181a, miR-223, miR-652) down-regulated and
three (miR-29a, miR-181a, miR-652) up-regulated miRNAs was
significantly and reliably associated with luminal A tumor (63).
Tissue miRNA-342 was highly expressed in luminal B tumor and
regarded as a very sensitive and specific biomarker this type of
breast cancer (64). Moreover, other miRNAs have been identify
to distinguish the remaining subtypes, such as basal-like (miR-
18a, miR-135b, miR-93, and miR-155), HER2 type (miR-142-
3p, and miR-150), and normal-like (miR-145, miR-99a, miR-100,
miR-130) (63–66, 75, 76).
Renal tumors have different genetic backgrounds, prognoses,
and responses to surgical and medical treatment, and their differ-
ential diagnosis is a frequent challenge for pathologists. Recently,
Youssef et al. developed a classification system that can identify the
different renal cell carcinoma (RCC) among four subtypes [RCC
clear cell RCC (ccRCC), papillary RCC (pRCC), oncocytoma
and chromophobe RCC (cRCC)] using a tissue-specific miRNAs
signature analysis. This method showed a sensitivity of 97% in
discriminating normal from RCC patients, 97% for pRCC from
chRCC and oncocytoma, 100% for the ccRCC subtype vs. others
subtype and chRCC vs. oncocytoma (67).
The remarkably heterogeneous nature of lung cancer has
become more apparent over the last decade. In general, advanced
lung cancer is an aggressive malignancy with a poor prognosis.
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TABLE 2 |miRNA for tumors sub-typing.
Cancer Specific miRNA Sources Expression Significance Reference
Breast cancer miR-29a, miR-181a, miR-223, miR-652 Blood Down (63)
miR-29a, miR-181a, miR-652 Blood Up
miR-342 Tissue Up Luminal B-like breast tumors vs. healthy
controls
(64)
miR-18a, miR-135b, miR-93, miR-155 Different Differential Basal-like vs. healthy controls (65, 66)
miR-145, miR-99a, miR-100, miR-130 Different Differential Normal-like vs. healthy controls
Renal cell carcinoma miR-195, miR-15b, miR-99a, miR-191 Tissue Up ccRCC vs. compared with other subtypes (67)
miR-200b Tissue Up Chromophobe RCC (chRCC) compared with
oncocytoma
(67)
miR-211 Tissue Up chRCC and oncocytoma vs. ccRCC and
pRCC
(67)
miR-210 Tissue Up Conventional RCC (cRCC) compared with
healthy controls
(56)
Lung Cancer MiR-21, miR-29b Tissue Up NSCLC vs. SCLC (68)
miR-21, miR-126, miR-210, miR-182 Serum Differential Diagnosis of stage-I NSCLC and also used in
lung adenocarcinoma vs. squamous cell
cancer
(49)
miR-205 Tissue Up Squamous vs. non-squamous NSCLC (69)
Pancreatic Cancer mR-375 Plasma Up Pancreatic ductal adenocarcinoma (PDAC) vs.
others pancreatic and gastric carcinoma
(57)
DLBCL miR-21, miR-155 and miR-221 different Up ABC-DLBCL vs. GCB-DLBCL subtypes (70)
miR-10393-3p Tissue Up Diagnosis of DLBL patients (71)
miR-10397-5p, NOVELMOO288M Tissue Up ABC-DLBCL vs. other DLBCL (71)
miR-5586-5p Tissue Up GCB-DLBCL vs. ABC-DLBCL and unclassified
DLBCL
(71)
miR-30b Tissue Down GCB-DLBCL vs. other DLBCL (71)
miR-515-3p, miR-155, miR-598, miR-625
miR-199a-5p
Tissue Differential PTCL-NOS vs. ALCL/ALK- (72)
miR-652, miR-627, miR-519e, miR-487b,
miR-324-5p, miR-449a, miR-381, miR-574-3p
Tissue Differential PTCL-NOS vs. AITL (72)
miR-124, miR-325, miR-181a, miR-618 Tissue Differential ALCL/ALK  vs. ALCL/ALK+ (72)
PTCL miR-512-3p, miR-886-5p, miR-886-3p,
miR-708, miR-135b
Tissue Up Diagnosis of ALCL/ALK+ disease vs.
ALCL/ALK  and other PTCLs
(73)
miR-146a, miR-155 Tissue Down
miR-210, miR-197, miR-191, miR-512-3p Tissue Up Diagnosis of ALCL/ALK  vs. ALCL/ALK+
and other PTCLs
(73)
miR-451, miR-146a, miR-22, miR-455-3p,
miR-455-5p, miR-143, miR-494
Tissue Down
ccRCC, clear cell renal carcinoma; chRCC, chromophobe renal cell carcinoma; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PDAC, pancreatic ductal
adenocarcinoma; DLBCL, diffuse large B-cell lymphoma; ABC, activated B cell-like; GCB, germinal center B cell like; PTCL, peripheral T-cell lymphoma; PTCL-NOS, PTCL-not
otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; ALCL/ALK+, ALCL  anaplastic lymphoma kinase present; ALCL/ALK ,
ALCL  anaplastic lymphoma kinase absent.
Each subtype is associated with molecular tests that define the
subtype and drugs that may potentially treat it.
Gilad et al. proved that eight miRNAs have high accuracy
(overall 94%), and high sensitivity (overall 96%) to distinguish
among the four subtypes of lung cancer [small cell lung can-
cer (SCLC), NSCLC, squamous cell carcinoma and carcinoid]
(77). Hsa-miR-21 and miR-29b are expressed at higher lev-
els in NSCLC versus SCLC and miR-129-3p, miR-205 can be
utilized to differentiate squamous from non-squamous NSCLC
(68, 69).
Diffuse large B-cell lymphoma is a common form of high-grade
non-Hodgkin lymphoma (NHL) that account for 30–40% of all
lymphoid malignancies. DLBCL includes a biologically and clin-
ically diverse set of diseases, many of which cannot be separated
from one another by well-defined criteria.
Many studies now suggest that DLBCL can be separated into
two groups on the basis of their gene expression profiles: acti-
vated B cell-like (ABC) and germinal center B cell like (GCB).
Recently, miRNAs have been used for characterization of DLBCL
subtypes. Lawrie et al. reported that three miRNAs (miR-21,
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miR-155, and miR-221) are significantly expressed in DLBCL
cases of ABC subtype as compared with GCB (70). Lim et al.
demonstrated that miR-10393-3p is significantly over-expressed
in DLBCL patients (71). Moreover, two miRNAs (miR-10397-5p,
NOVELMOO288M) can distinguish ABC-DLBCL patients from
other DLBCL patients (71). Furthermore, miR-5586-5p can be
used for distinguish GCB-DLBCL from ABC-DLBCL, and miR-
30b can also be used to discriminate GCB-DLBCL from other
DLBCL disease group (71).
Peripheral T-cell lymphoma (PTCL) is a NHL, which refers
to a diverse group of uncommon and aggressive nodal, extra
nodal, and leukemic tumors that represent about 10–15% of all
lymphoid neoplasm. The most common subtypes of PTCL are
PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic
T-cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL)
anaplastic lymphoma kinase present (ALK+), and ALCL/ALK 
(72, 78). Specifically, PTCL-NOS is a rare and life-threatening
disease whose differential diagnosis from AITL and ALCLs are
still challenging. Most recently, Laginestra et al. validated a five
miRNAs set (miR-515-3p, miR-155, miR-598, miR-625, miR-
199a-5p) that can differentiate PTCL-NOS from ALCL/ALK ,
a eight miRNAs panel (miR-652, miR-627, miR-519e, miR-487b,
miR-324-5p, miR-449a, miR-381, miR-574-3p) that can be used
to distinguish PTCL-NOS from AITL, and also a four miRNAs
signature (miR-124, miR-325, miR-181a, miR-618) that can be
used to identify ALCL/ALK  from ALCL/ALK+ disease group
(72). Liu et al. confirmed two miRNA signatures that can be
used as a diagnostic tool for biological difference of PTCLs sub-
typing, and can play a crucial role in pathogenesis. In the first
miRNA signature, the levels of five miRNAs (miR-512-3p, miR-
886-5p, miR-886-3p, miR-708, miR-135b) are up-regulated, and
levels of twomiRNAs (miR-146a, miR-155) are down-regulated as
compared to ALCL/ALK+ disease group from ALCL/ALK , and
other PTCLs disease group (73). Moreover, the second miRNA
signature is used to differentiateALCL/ALK  fromALCL/ALK+,
and other PTCLs disease group (Table 2) (73).
miRNAs in Diagnosis in Other Diseases
Cardiovascular diseases (CVD) still represent the primary cause
of morbidity and mortality worldwide. The understanding and
the identification of CVDmolecular factors that may significantly
reduce the patient death rates still remain a challenge (74). Pro-
tein biomarkers, such as cardiac troponin (cTn), CK-MB, brain
natriuretic peptide (BNP), and N-terminal prohormone (NT-
proBNP), have been used to identify and monitor myocardial
damage. Unfortunately, these biomarkers provided false posi-
tive results and are also time-dependent (79, 80). Therefore, for
early diagnosis of cardiac damage other types of biomarker are
the need of the hour. miRNAs have been proven to have an
important role in CVD, including acute myocardial infarction
(AMI), hypertrophy, heart failure, arrhythmias, and atheroscle-
rosis (81). Tijsen et al. demonstrated that blood miR-423-5p
was highly expressed in heart failure patients (independent of
age and gender) and might represent a significant and sensitive
biomarker for heart disease (82). Recently, it has been reported
that elevated plasma levels of this miR are positively linked
with NT-proBNP levels in dilated cardiomyopathy heart failure
patients (83).
D’Alessandra et al. reported that plasma levels of miR-1, miR-
133a/bwere elevated 156 72min after the onset AMI symptoms;
whereas plasma levels of miR-122 and miR-375 were lower only
ST-segment elevation myocardial infarction (STEMI) patients
than in healthy controls (84). Other studies showed that plasma
levels of miR-21, miR-1, miR-26, miR-133, miR-30, miR-328, and
miR-499 were significantly expressed in atrial fibrillation (85).
Takotsubo cardiomyopathy (TTC), a type of non-
ischemiccardio myopathy unrelated to AMI, is a major
life-threatening condition. To date, there are not early biomarker
for its diagnosis and its distinction from AMI. Jaguszewski et al.
reported that a unique signature comprising miR-1, miR-16,
miR-26a, and miR-133a is capable of distinguish TTC from
healthy individuals (sensitivity 74.19%, specificity78.57%) and
from AMI patients (sensitivity 96%, specificity70.37%) (86).
Diabetes mellitus (DM) is a metabolic shuffle identified by
hyperglycemia-mediated life-threatening complications. Many
studies showed that circulating miRNAs are linked with type 1,
2, and gestational DM and its complications. Levels of circulating
miR-21 and miR-210 were significantly high in the plasma and
urine of the type 1 diabetic patients, while in urine miR-126 was
notably lower in type-1 diabetic patients compare to controls
(87). Peng et al. showed that the levels of urinary miR-29a were
significantly high in albuminuria with type 2 DM than in healthy
controls and urinary miR-29b was correlated with carotid intima-
media thickness (cIMT) in patients with type 2 diabetes (88).
In addition, the levels of platelet and plasma miR-223 and miR-
146a were significantly reduced in patients with ischemic stroke
and DM or only DM (89). Recently, Luo et al. demonstrated
that platelet-derived miR-103b was specifically, down-regulated
in early type 2 DM (90).
HIV/AIDS is a spectrum of conditions caused by infection with
the human immunodeficiency virus type 1 and 2. For diagno-
sis of HIV/AIDS, several types of tests can help the physician
to determine the patients HIV infection status, to calculate the
evolution of the disease, and to monitor the efficacy of anti-
retroviral therapy. Several studies demonstrated that host–virus
interactions (including HIV) are controlled, at least in part, by
miRNAs and these might lead to new diagnostic and attractive
therapeutic strategies. Recently, Monteleone et al. proved that
plasma miR-29b was highly expressed in HIV-1 patients, while
lower levels of plasma miR-29cindicated high viremia, low CD4+
T cell count and high levels of integrated HIV-1 DNA, suggesting
that the miR-29 family could be implicated in the natural history
of HIV-1 infection (91). Another group reported that plasma
levels of two miRNAs (miR-150 and miR-146b-5p) also varied
between different groups ofHIV patients and between patients
and healthy individuals (92). Moreover, expression levels of miR-
150 in peripheral blood mononuclear cells (PBMCs) and plasma
might be a better and specific biomarker for diagnosis of the dif-
ferent status of HIV/AIDS disease. MiR-150 levels were decreased
in PBMCs but increased in plasma of HIV patients and drug-
resistant HIV patients. On the other hand, miR-150 levels were
increased in PBMCs and decreased in plasma of anti-retroviral
therapy patients (92). In addition, Sekar et al. reported thatmiR-21
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TABLE 3 | Circulating miRNAs a potential diagnostic biomarkers in other disease.
Disease miRNA Source Expression Significance Reference
Cardiovascular
disease
miR-423-5P Blood Up Diagnosis of heart failure patients
compared to healthy controls
(74, 73)
miR-1, miR-133a/b Exosomes Up Diagnosis of AMI, and biomarker for
cardiomyocyte death disease
(79)
miR-122 and miR-375 Plasma Up STEMI patients vs. healthy controls
miR-21, miR-1, miR-26, miR-133,
miR-30, miR-328, and miR-499
plasma Up Diagnosis of arterial fibrillation specific
heart disease vs. healthy controls
miR-1, miR-16, miR-26a, and miR-133a Sera Up TTC vs. healthy controls (81)
Diabetic mellitus miR-21 and miR-210 Urine and plasma Up Type-1 diabetic patients vs. healthy
controls
(82)
miR-29a Urine Up Albuminuria with type2 diabetes mellitus
vs. healthy controls
(83)
miR-223 and miR-146a Plasma, platelet Down Diagnosis of ischemic stroke and
diabetes mellitus or only diabetes
mellitus compared to controls
(84)
miR-130b Blood Down Diagnosis early type 2 diabetes mellitus (85)
HIV/AIDS miR-29b Plasma Up HIV1 patients vs. controls (86)
miR-29c Plasma Down High viremia, low cd4+ T cells
miR-150 and miR-146b-5p Plasma Differential HIV patients vs. controls (87)
miR-21 Plasma Up Diagnosis of HIV-related lymphomas (88)
miR-122 Plasma Up Diagnosis HIV/HCV co-infection (89)
Forensic Nine miRNA panel (miR-451, miR-16,
miR-135b, miR-10b, miR-658, miR-205,
miR-124a, miR-372, miR-412)
Blood, semen, saliva,
vaginal secretions
menstrual blood
Differential Sensitive biomarkers identification of
forensic biological stains
(90)
AMI, acute myocardial infarction; STEMI, ST-segment elevation myocardial infarction; TTC, Takotsubo cardiomyopathy.
over-expression is considerably associated with the onset of HIV-
related lymphomas (93). Furthermore, the levels of extracellu-
lar miR-122 were highly expressed in HIV/HCV co-infected
patients (94).
Use of miRNAsin Forensic Diagnostic
Isolating the origin of body fluids in a crime scene would be
instrumental for its reconstruction; however, conventional pro-
tein based methods for body fluid identification are prone to var-
ious limitations, such as sample consumption, varying degrees of
sensitivity and specificity, and for mRNA based markers, stability.
The shorter lengths of miRNAs make them less susceptible to
degradation caused by chemical and/or physical environmental
factors, thus rendering them useful biomarkers for body fluid
identification.
Hanson et al. showed the expression of miRNAs in dried
forensically relevant biological fluids: blood, saliva, menstrual
blood, and vaginal secretion. They distinguished nine panels of
miRNAs that are differentially expressed and can be used as
sensitive biomarkers to identify the origin of body fluid of forensic
biological stains(95) (Table 3).
Experimental Techniques and
Normalization of Circulating microRNAs
Accurate measurement of tissue and body fluid miRNAs has
clinical importance for diagnosis and prognosis of several types
of disease. miRNAs detection is a very challenging task for their
native properties, e.g., small size, scarce concentration, high risk of
cross-hybridization, and tissue/stage-specific expression. There-
fore, quantification of cell-free miRNAs needs powerful tools.
The rapid improvement of diagnostic device platforms is one
of the leading experimental goals in the world of life science
research and medical diagnostics. The explosion of high interest
in miRNAs, over the recent years, brought to the development of
many platforms. High-throughput miRNA profiling techniques
including qRT-PCR, microarray, deep sequencing or next gen-
eration sequencing (NGS), and nanopores are effective tools for
obtaining expression profiles of extracellularmiRNAs. These tech-
niques highly smoothen the process of free cell miRNA expression
profiling. In this view, high-throughput techniques are better to
the existing low-throughput techniques such as northern bolting
and in situ hybridization (ISH) (96). Currently, qRT-PCR is the
most common, reliable and available, inexpensive method used
for quantifying the small amount of miRNAs with the high sen-
sitivity and specificity and the subsequent validation of clinical
samples (96, 97). However, some limitations of qRT-PCR, such
as normalization of data and primer design, can highly influence
the results. The lack of standardized housekeeping RNA for nor-
malization, especially in body fluid, is a critical issue (97). Many
miRNAs can be used as control reference such as miR-16, miR-
142-3p,miR-30b,miR-145,miR-93, U6, U6B, SNORD68, RNU48,
RNU43, RNU62, and 5sRNA. Kirschner et al. reported that miR-
16 is highly expressed in red blood cells and that its levels in the
extracellular content of blood fluids can differ significantly due
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to hemolysis (98). Moreover, many studies suggested that several
endogenous genes might be diseases specific. Therefore, some
miRNAs, such as miR-16 and miR-93 and SNORD68, might be
considered satisfactory reference gene formiRNAs serum analysis
of gastric and urologic cancers, respectively (99, 100). At present,
there is no unique housekeeping RNA that can be used as the
standard endogenous reference gene in normalizing circulating
miRNAs. Currently, many studies suggest the use of more than
one reference genes or better a combination for normalizing
circulating miRNA concentrations.
Perspective
An optimal biomarker should be sensitive, specific, non-invasive,
and comparable to the disease conditions. In the new decade,
many studies clearly proved that cell-free, miRNAs, and tissue
miRNAs fulfill these expectations.
Despite the encouraging progress in the practical areas, sev-
eral major theoretical and technical difficulties remain to be
addressed. First, more basic investigations will be required to fur-
ther examine the functional role of miRNAs in cancer, cardiovas-
cular, and other disease. Although, miRNAs can inhibit mRNAs
by translational repression or cleavage, others possible unknown
mechanism could lead to translational or post-translation repres-
sion. Second, the biological functions and packaging of extracel-
lular miRNAs needs to be better elucidated. A limited number of
studies proposed that microvesicles containing miRNAs might be
involved in the tumor microenvironment. Finally before transla-
tion into clinical practice, all circulating miRNA findings require
further steps of validation and an accurate standardization of all
preanalytical and analytical procedures, in order to control for all
potential technical biases.
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